As several previous studies have shown that PRMT5 inhibition leads to cell cycle arrest, we next sought to determine whether the KRAS mutant CRC cells would show a greater rate of cell cycle arrest after 60 h of 10 μM PRMT5 inhibitor treatment when compared to the KRAS WT CRC cells [26,38]. Here, KRAS is linked to colorectal carcinoma.